Table 1 The basic clinical characteristics of patients in this study
Variables | Range |
|---|---|
Male: Female | 54 (17.3%): 258 (82.7%) |
Age (years) | 45.07 ± 12.79 |
Duration of Graves’ hyperthyroidism (months) | 6 (1, 376) |
Thyroid weight (g) | 52.21 (19.12, 239.00) |
ATD therapy history (Male: Female) | 42 (77.8%): 205 (80.7%) |
Propyltiouracil (Male: Female) | 5 (11.9%): 26 (12.7%) |
Methimazole (Male: Female) | 37 (88.1%): 179 (87.3%) |
FT3 (pmol/L) | 22.08 (4.35, 36.70) |
FT4 (pmol/L) | 51.68 (3.51, 154.80) |
TSH (uIU/mL) | 0.005 (0.001, 0.250) |
TPOAb (IU/mL) | 1300 (23.30, 1300.00) |
TRAb (IU/mL) | 12.72 (0.30, 40.00) |
2-h RAIU | 37.25 (7.80, 83.69) |
6-h RAIU | 66.24 (14.40, 95.62) |
24-h RAIU | 72.52 (27.29, 99.90) |
6/24-h uptake ratio | 92.07 (49.48, 126.70) |
Dose of RAI (mCi) | 8.81 ± 2.90 |